hypothesis™ Earns Three 2026 Skin Anarchy Top Pick Awards Across Acne and Eczema Care

Precision skincare brand recognized for patented products that target harmful bacteria without disrupting the skin microbiome

EMERYVILLE, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Hypothesis™, the precision skincare brand built on patented enzyme technology, today announced that three of its products won the 2026 Skin Anarchy Top Picks Beauty Awards. Recognized for innovation across both acne and eczema treatment, these award-winning products selectively target the harmful bacteria driving breakouts and flare-ups while preserving the broader skin microbiome, avoiding the collateral damage associated with conventional broad-spectrum treatments.

Presented annually by Skin Anarchy, a leading skincare media platform focused on science-backed beauty and innovation, the annual Top Picks award program recognizes standout skincare that combines scientific innovation with proven performance.

Three hypothesis™ products earned 2026 Skin Anarchy Top Pick recognition:

Acne Precision Serum earned Top Pick in the Serum category for delivering targeted acne treatment while remaining gentle enough for daily use. Powered by CUT-02™, 97% of clinical trial participants saw fewer breakouts, with 95% finding the formula non-irritating.
Precision Microdart Blemish Patches earned Top Pick in the Patches category for using dissolvable microdarts to deliver CUT-02™ below the skin's surface, helping stop early-stage pimples before they fully develop.
Eczema Precision Hydrogel earned Top Pick in the Treatment category. Formulated with TPZ-01™, this hydrogel is clinically proven to be 2.5 times more effective than a standard colloidal oatmeal treatment at reducing eczema symptoms while preserving the skin's beneficial microbiome.

While each of these products serves a different purpose, all three are built on the same patented precision enzyme technology. Hypothesis™ developed precision enzymes that selectively target harmful bacteria while preserving the skin's beneficial microbiome. TPZ-01™ targets Staphylococcus aureus, while CUT-02™ targets acne-causing C. acnes.

"We set out to develop products that work with the skin rather than against it," said Oliver Liu, PhD, co-founder of hypothesis™. "The three Skin Anarchy Top Pick recognitions across multiple categories reinforce that this precision approach can solve a wide range of skincare challenges."

The recognition continues a strong year for hypothesis™. The brand received Skin Anarchy's 2026 Science of Skin Award recognizing scientific validity and demonstrated product efficacy. It was also recently named a finalist in the 2026 BeautyMatter Awards in the Best Breakthrough Technology (Ingredient) and Best Wellness Product (Topicals) categories, with the winner announcement expected in December.

Hypothesis™ products are available at www.hypothesis.bio and Ulta.com.

About hypothesis™

Founded in 2022 and based in Emeryville, CA, hypothesis™ is a precision skincare company developing patented enzyme-based products that selectively target the bacteria associated with inflammatory skin conditions such as eczema and acne while preserving the broader skin microbiome. Its formulas have earned the National Eczema Association Seal of Acceptance, EWG Verified®, Microbiome Friendly for Eczema certification from MyMicrobiome, and Leaping Bunny Certified status. Visit us at www.hypothesis.bio.

Attachments

Jo-Anne Coombes
hypothesis
jo-anne.coombes@teambespoke.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.